Stocks Health care TRDA
NASDAQ · Health careEntrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. brought in $4M of revenue over the twelve months to September 30, 2026, down 93.5% from a year earlier. It posted a net loss of $161.4M. In fiscal 2025 capital spending exceeded operating cash flow by $129.6M. At September 30, 2026 it held $112.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Entrada Therapeutics, Inc.
- Net worth
- Entrada Therapeutics, Inc. has a market value (market cap) of $197.8M at the latest share price, and shareholders' equity of $198.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $25.4M (-87.9% year on year), with a net loss of $143.8M. Over the 12 months to September 30, 2026: revenue $4M, net loss $161.4M.
- Cash flow
- In fiscal 2025 operations used $128.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Entrada Therapeutics, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Entrada Therapeutics, Inc. does
Entrada Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TRDA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $25.4M | -$143.8M | -$3.47 | -$129.6M |
| 2024 | $210.8M | $65.6M | $1.68 | -$44.7M |
| 2023 | $129M | -$6.7M | -$0.20 | $134.2M |
| 2022 | n/a | -$94.6M | -$3.02 | -$96.7M |
| 2021 | n/a | -$51.2M | -$8.16 | -$55.4M |
| 2021 | n/a | -$26.5M | -$24.00 | -$27.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TRDA ranks in Health care
Latest SEC filings
What Entrada Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 44% to $905K versus the same quarter last year; diluted EPS -$0.94 versus -$1.06.
- November 5, 2026
- October 14, 2026
- September 10, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 54% to $898K versus the same quarter last year; diluted EPS -$1.01 versus -$1.04.
- August 5, 2026
- June 10, 2026
- May 19, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 96% to $875K versus the same quarter last year; diluted EPS -$0.95 versus -$0.42.
Insider trades
What the people running Entrada Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $7.2M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 9, 2026 | MPM BioVentures 2014, L.P.10% owner | Soldindirect | 28,837 | $205.6K |
| September 9, 2026 | Mpm Bioventures 2018, L.P.10% owner | Soldindirect | 28,837 | $205.6K |
| September 8, 2026 | MPM BioVentures 2014, L.P.10% owner | Soldindirect | 192,500 | $1.4M |
| September 8, 2026 | Mpm Bioventures 2018, L.P.10% owner | Soldindirect | 192,500 | $1.4M |
| September 4, 2026 | MPM BioVentures 2014, L.P.10% owner | Soldindirect | 38,500 | $273.7K |
| September 4, 2026 | Mpm Bioventures 2018, L.P.10% owner | Soldindirect | 38,500 | $273.7K |
| September 3, 2026 | MPM BioVentures 2014, L.P.10% owner | Soldindirect | 32,263 | $231.3K |
| September 3, 2026 | Mpm Bioventures 2018, L.P.10% owner | Soldindirect | 32,263 | $231.3K |
Who owns TRDA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Baker Bros. Advisors LP13D, may seek influence with 3 related filers | 13.2% | June 26, 2024 |
| Kush Parmar13D, may seek influence with 6 related filers | 10.8% | November 18, 2025 |
| Ansbert Gadicke13D, may seek influence with 12 related filers | 9.9% | September 10, 2026 |
| Roche Finance Ltd13G, passive with 1 related filers | 6.9% | February 14, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 129 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Baker Bros. Advisors LP | 5,072,730 | 0 |
| 5AM Venture Management, LLC | 4,056,379 | 0 |
| BlackRock, Inc. | 2,583,333 | +224,540 |
| Merck & Co., Inc. | 1,739,768 | new |
| Vanguard Capital Management LLC | 1,269,634 | +13,621 |
| Mpm Bioimpact LLC | 1,253,053 | new |
| TCG Crossover Management, LLC | 1,060,230 | -1,227,270 |
| Wellington Management Group Llp | 954,419 | -80,363 |
| Millennium Management LLC | 763,959 | +244,603 |
| StepStone Group LP | 761,277 | 0 |
| Geode Capital Management, LLC | 717,430 | +50,083 |
| Aqr Capital Management LLC | 699,537 | +620,044 |
| Nantahala Capital Management, LLC | 601,150 | +441,818 |
| State Street Corp | 596,677 | +62,879 |
| Jpmorgan Chase & Co | 496,457 | +481,610 |
| Citadel Advisors LLC | 394,323 | +179,305 |
| Dimensional Fund Advisors LP | 376,136 | +51,665 |
| Northern Trust Corp | 309,942 | +74,950 |
| Jacobs Levy Equity Management, Inc | 303,459 | -30,455 |
| Vanguard Portfolio Management LLC | 254,130 | +33,636 |
Insiders
10 insiders reported holding 18,986,605 shares in total, about $96.5M at the last price.
| Holder | Shares |
|---|---|
| Baker Bros. Advisors LP10% owner | 4,691,3924,691,392 held indirectly |
| Mpm Bioventures 2018, L.P.10% owner | 3,885,1153,885,115 held indirectly |
| MPM BioVentures 2014, L.P.10% owner | 3,885,1153,885,115 held indirectly |
| 5AM Ventures V, L.P.10% owner | 2,783,781 |
| Parmar KushDirector | 2,691,3372,691,337 held indirectly |
| Doshi DipalCEO, Director | 517,290 |
| Sethuraman NatarajanPresident, Research & Develop. | 214,238 |
| Dowden Nathan JPresident & COO | 196,060 |
| Wentworth Kory JamesChief Financial Officer | 117,277 |
| Zeiher Bernhardt GDirector | 5,0005,000 held indirectly |
Questions about TRDA
What does Entrada Therapeutics, Inc. do?
Entrada Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TRDA. Its shares trade on NASDAQ under the ticker TRDA.
What is Entrada Therapeutics, Inc.'s net worth?
Entrada Therapeutics, Inc. has a market value (market cap) of $197.8M at the latest share price, and shareholders' equity of $198.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Entrada Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $161.4M on revenue of $4M.
How much revenue does Entrada Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Entrada Therapeutics, Inc. reported revenue of $4M. That is 93.5% less than a year earlier.
When did Entrada Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Entrada Therapeutics, Inc.'s next earnings report?
Entrada Therapeutics, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TRDA with
Follow TRDA
Get an email when Entrada Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Entrada Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.